NMN (Nicotinamide Mononucleotide)

The NAD+ Precursor for Cellular Energy and Longevity

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose, nicotinamide, and a phosphate group. It serves as one of the most direct biosynthetic precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme found in every living cell and essential for hundreds of metabolic reactions. NAD+ is the second most abundant molecule in the body after water and is required for processes including cellular energy production, DNA repair, gene expression, and immune regulation.

NAD+ levels decline significantly with age. By middle age, circulating NAD+ concentrations may fall to roughly half of youthful levels. This decline is associated with mitochondrial dysfunction, increased oxidative stress, impaired DNA repair, chronic inflammation, metabolic disorders, and accelerated aging. Restoring NAD+ levels through precursor supplementation has emerged as one of the most promising strategies in longevity and anti-aging research.

NMN occupies a unique position in NAD+ biosynthesis because it is only one enzymatic step away from NAD+ itself. Once inside the cell, the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) converts NMN directly into NAD+. This makes NMN a highly efficient NAD+ booster compared to more upstream precursors. NMN is found naturally in trace amounts in foods such as broccoli, cabbage, edamame, avocados, cucumbers, and tomatoes, though dietary intake alone provides far less than supplemental doses.

Molecular formula: C₁₁H₁₅N₂O₈P

Molecular weight: 334.22 g/mol

CAS number: 1094-61-7

Appearance: White to off-white crystalline powder

Solubility: Highly soluble in water

Bioavailability: Rapidly absorbed orally; sublingual administration may enhance uptake

How It Works

NAD+ Biosynthesis and the Salvage Pathway

The body produces NAD+ through three main pathways: the de novo pathway (from tryptophan), the Preiss-Handler pathway (from nicotinic acid), and the salvage pathway (from nicotinamide). The salvage pathway is the dominant route for maintaining NAD+ homeostasis in most tissues. In this pathway, the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT) converts nicotinamide (NAM) into NMN. NMN is then converted to NAD+ by NMNAT enzymes. Supplemental NMN bypasses the rate-limiting NAMPT step, feeding directly into the final conversion to NAD+.

Cellular Uptake of NMN

NMN enters cells through multiple routes. A dedicated NMN transporter, encoded by the gene Slc12a8, was identified in 2019 and is expressed at particularly high levels in the small intestine. NMN can also be converted extracellularly to nicotinamide riboside (NR) by the enzyme CD73, after which NR enters cells through equilibrative nucleoside transporters and is re- phosphorylated back to NMN by nicotinamide riboside kinase (NRK) inside the cell. Recent research also indicates that gut microbiota play a role in NMN metabolism, with certain bacterial species facilitating deamidation pathways that contribute to NAD+ synthesis through the Preiss- Handler route.

Sirtuin Activation

Sirtuins are a family of seven NAD+-dependent deacetylase and ADP-ribosyltransferase enzymes (SIRT1 through SIRT7) that regulate critical cellular functions including DNA repair, gene silencing, mitochondrial biogenesis, inflammation, and cellular stress responses. Sirtuins require NAD+ as a co-substrate, meaning their activity is directly dependent on NAD+ availability. By raising NAD+ levels, NMN supplementation enhances sirtuin activity, which in turn supports genomic stability, metabolic efficiency, and cellular resilience against age-related decline.

PARP Activation and DNA Repair

Poly(ADP-ribose) polymerases (PARPs) are another major family of NAD+-consuming enzymes. PARP1 in particular plays a critical role in detecting and repairing DNA single-strand breaks. As organisms age, accumulated DNA damage increases PARP activity, further depleting NAD+ stores and creating a vicious cycle of declining repair capacity. NMN supplementation helps replenish the NAD+ pool consumed by PARP activity, supporting the body’s capacity to maintain genomic integrity.

Mitochondrial Function and Energy Metabolism

NAD+ is essential for mitochondrial electron transport chain activity, where it serves as a primary electron carrier in the form of NADH. Adequate NAD+ levels are required for efficient oxidative phosphorylation and ATP production. Age-related NAD+ depletion leads to mitochondrial dysfunction, reduced energy output, and increased reactive oxygen species (ROS) generation. NMN supplementation has been shown in preclinical models to restore mitochondrial membrane potential, increase oxygen consumption rates, and improve overall cellular energy metabolism.

CD38 and NAD+ Consumption

CD38 is an ectoenzyme whose expression and activity increase with age and chronic inflammation. CD38 is one of the largest consumers of intracellular NAD+, and its upregulation during aging is considered a major driver of age-related NAD+ decline. Studies have shown that CD38 knockout mice maintain higher NAD+ levels and exhibit protection against metabolic dysfunction. NMN supplementation can help counteract the NAD+-depleting effects of CD38, though combining NMN with CD38 inhibitors such as apigenin or quercetin may further optimize NAD+ restoration.

Benefits

Cellular Energy and Mitochondrial Health

NMN has been shown in preclinical studies to restore mitochondrial function in aged tissues, improve ATP production, and enhance overall cellular energy metabolism. Multiple human clinical trials have reported improvements in physical energy, reduced fatigue, and better exercise tolerance with NMN supplementation at doses ranging from 250 mg to 1,200 mg per day.

Anti-Aging and Longevity

The NAD+ decline associated with aging is considered one of the central hallmarks of the aging process. NMN supplementation directly addresses this decline by replenishing NAD+ stores and activating sirtuins and PARPs, the key enzymatic pathways that maintain genomic stability and cellular homeostasis. In a 60-day randomized controlled trial, blood biological age increased significantly in the placebo group but remained unchanged in all NMN-treated groups, suggesting a potential slowing of biological aging.

Metabolic Health and Insulin Sensitivity

NMN supplementation has demonstrated benefits for metabolic health in both animal and human studies. In overweight or obese postmenopausal women with prediabetes, 250 mg of NMN daily for 10 weeks improved skeletal muscle insulin sensitivity and insulin signaling. A 2023 clinical trial found that NMN significantly reduced total cholesterol, LDL cholesterol, non-HDL cholesterol, body weight, and diastolic blood pressure in healthy middle-aged participants over 12 weeks.

Physical Performance and Exercise Capacity

Several clinical trials have examined the effects of NMN on physical performance. A randomized, double-blind study in amateur runners found that NMN supplementation (at 300 mg, 600 mg, and 1,200 mg per day) enhanced aerobic capacity and increased the ventilatory threshold in a dose-dependent manner over six weeks. A multicenter trial involving 80 middle- aged adults showed that NMN significantly increased six-minute walking distance compared to placebo at all tested doses (300 mg, 600 mg, and 900 mg per day). A meta-analysis of nine studies including 412 participants found that NMN had significant positive effects on gait speed and muscle mass.

Cognitive Function and Neuroprotection

NAD+ plays essential roles in neuronal health, including supporting synaptic plasticity, axonal maintenance, and protection against neurodegenerative processes. Preclinical studies have demonstrated that NMN protects against neuronal damage in models of Alzheimer’s disease, ischemia, and age-related cognitive decline. NMN has also been shown to attenuate cognitive dysfunction in sepsis-associated encephalopathy models through SIRT1-dependent mechanisms. While human studies on NMN and cognitive function are still emerging, the strong preclinical evidence supports NMN’s potential for brain health.

Cardiovascular Health

NMN supplementation has shown cardiovascular benefits in both preclinical and clinical settings. In human trials, NMN reduced blood vessel stiffness and diastolic blood pressure, particularly in participants with higher-than-average blood glucose levels. Animal studies have demonstrated that NMN protects the heart from ischemic damage, reduces vascular endothelial dysfunction, and improves arterial elasticity. These effects are mediated through NAD+- dependent activation of SIRT1 and improved endothelial nitric oxide production.

Sleep Quality

A double-blind, randomized, placebo-controlled study in older Japanese adults found that 250 mg of NMN taken daily for 12 weeks significantly improved sleep quality as measured by the Pittsburgh Sleep Quality Index. Participants also experienced reduced daytime drowsiness and improved physical performance markers. These findings suggest that NMN’s effects on NAD+ and circadian rhythm-regulating sirtuins may contribute to better sleep architecture in aging populations.

Gut Health

Emerging research indicates that NMN supplementation positively influences the gut microbiome. Animal studies have shown that NMN increases the abundance of beneficial bacteria, including butyric acid-producing species and Akkermansia muciniphila, while reducing populations of harmful bacteria. NMN also increased the number of goblet cells, enhanced mucus thickness, and improved expression of tight junction proteins, all of which contribute to maintaining intestinal barrier integrity.

What the Science Shows

Key Human Clinical Trials

Irie et al. (2020) – First Human Safety Study

Design: Single-arm, open-label study in 10 healthy Japanese men. Participants received single oral doses of 100 mg, 250 mg, and 500 mg NMN. Results: NMN was safe and well tolerated at all doses. No significant changes in heart rate, blood pressure, or oxygen saturation were observed within five hours of administration. Blood levels of NMN metabolites, including NAD+, increased in a dose-dependent manner. Significance: This was the first clinical study to confirm the safety and tolerability of oral NMN in humans.

Yoshino et al. (2021) – Insulin Sensitivity in Prediabetic Women

Design: Randomized, double-blind, placebo-controlled trial. 25 overweight or obese postmenopausal women with prediabetes received 250 mg NMN daily for 10 weeks. Results: NMN supplementation significantly increased skeletal muscle insulin sensitivity, improved insulin signaling, and increased NAD+ levels in peripheral blood mononuclear cells. Significance: This was among the first trials to demonstrate metabolic benefits of NMN in a clinical population at risk for type 2 diabetes.

Huang et al. (2022) – Uthever Multicentre Trial

Design: Randomized, double-blind, placebo-controlled, parallel-group trial in 66 healthy adults aged 40 to 65. Participants took 300 mg NMN or placebo daily for 60 days. Results: NAD+/NADH levels increased by 38% at day 60 compared to baseline. SF-36 health questionnaire scores improved by 6.5% in the NMN group versus 3.4% in placebo. The HOMA- IR insulin resistance index rose 30.6% in the placebo group but only 0.6% in the NMN group. Significance: Demonstrated that moderate-dose NMN effectively raises NAD+ levels and improves subjective health markers in middle-aged and older adults.

Kim et al. (2022) – Sleep Quality in Older Adults

Design: Randomized, double-blind, placebo-controlled study in older Japanese adults. Participants received 250 mg NMN daily for 12 weeks. Results: NMN significantly improved sleep quality (Pittsburgh Sleep Quality Index), reduced daytime drowsiness, and improved lower-limb function and walking speed. Significance: One of the first studies to demonstrate NMN’s benefits for sleep and motor function in the elderly.

Yi et al. (2022) – Dose-Dependent Multicenter Trial

Design: Randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose- dependent trial. 80 healthy middle-aged adults received placebo, 300 mg, 600 mg, or 900 mg NMN daily for 60 days. Results: Blood NAD+ concentrations significantly increased in all NMN groups compared to placebo and baseline at days 30 and 60. The six-minute walking distance was significantly greater in all NMN groups. Blood biological age increased in the placebo group but remained unchanged in all NMN-treated groups. SF-36 health scores were significantly better in NMN groups. Optimal efficacy was observed at 600 mg daily. No safety concerns were identified at any dose. Significance: The largest and most rigorous dose-response NMN trial to date, establishing 600 mg as an optimal daily dose for NAD+ boosting and functional improvement.

Liao et al. (2021) – Aerobic Capacity in Runners

Design: Randomized, double-blind study in amateur runners over six weeks. Participants received 300 mg, 600 mg, or 1,200 mg NMN daily alongside exercise training. Results: NMN supplementation improved ventilatory threshold and aerobic capacity in a dose-dependent manner, with the greatest benefits observed at higher doses. Significance: Demonstrated that NMN enhances exercise performance and aerobic capacity in physically active individuals.

Katayoshi et al. (2023) – Cholesterol, Weight, and Blood Pressure

Design: Randomized, double-blind, placebo-controlled trial. 36 healthy middle-aged participants received 125 mg NMN twice daily (250 mg total) for 12 weeks. Results: NMN safely increased NAD+ levels and significantly reduced total cholesterol, LDL cholesterol, non-HDL cholesterol, body weight, and diastolic blood pressure. Vascular stiffness was also reduced. Significance: Demonstrated broad cardiometabolic benefits of NMN at a moderate dose in healthy adults.

Yamaguchi et al. (2024) – Safety at High Doses

Design: Safety study evaluating oral administration of 1,250 mg NMN daily for four weeks in healthy adult men and women aged 20 to 65. Results: NMN was safe and well tolerated with no significant adverse events, no changes in vital signs, and no abnormalities in laboratory parameters. Significance: Confirmed the safety of NMN at doses significantly higher than those used in most efficacy trials, supporting the tolerability of up to 1,250 mg daily.

Meta-Analyses and Systematic Reviews

A 2024 systematic review and meta-analysis of nine studies including 412 participants found that NMN had significant positive effects on gait speed and muscle mass in middle-aged and elderly individuals. The analysis also found improvements in ALT (liver enzyme) levels and suggested that lower doses of NMN had the most prominent impact on insulin resistance (HOMA-IR). A separate meta-analysis of eight randomized controlled trials (342 participants, published 2021–

2023) confirmed that NMN effectively boosts blood NAD+ levels and provides moderate improvement in triglyceride levels, particularly in overweight or obese participants.

Dosing Protocol

Standard Oral Dosing

NMN is available as a powder, sublingual tablet, or capsule. Based on the available clinical trial data, the following general dosing guidelines have been established:

Protocol Daily Dose Notes Beginner / Maintenance 250–300 mg/day Good starting point; demonstrated NAD+ increase and subjective health benefits Optimal / Standard 500–600 mg/day 600 mg showed peak efficacy for NAD+ levels and physical performance in clinical trials Advanced / Athletic 900–1,200 mg/day Higher doses used in exercise performance and high-dose safety studies; 1,250 mg confirmed safe

Dosing by Application

Application Suggested Dose Duration Studied General anti-aging 250–600 mg/day 8–12 weeks Metabolic / insulin sensitivity 250 mg/day 10 weeks Cardiovascular support 250 mg/day 12 weeks Exercise performance 600–1,200 mg/day 6 weeks Sleep improvement 250 mg/day 12 weeks NAD+ restoration 300–900 mg/day 30–60 days

Administration Guidelines

Timing: Most clinical trials administered NMN once daily in the morning before breakfast. Morning dosing aligns with the body’s circadian NAD+ synthesis patterns and may help avoid potential sleep disruption from evening administration.

Method: NMN powder can be taken orally dissolved in water, placed under the tongue (sublingual) for enhanced absorption, or consumed in capsule form. Sublingual administration allows NMN to bypass first-pass liver metabolism and enter the bloodstream more directly.

With or without food: Most clinical trials administered NMN on an empty stomach. NMN is rapidly absorbed through the small intestine, with measurable increases in blood NAD+ metabolites observed within minutes of oral ingestion.

Companion supplements: Many researchers and practitioners recommend co-supplementation with trimethylglycine (TMG, 500–1,000 mg/day) to support methylation balance, as NAD+- consuming enzymes generate nicotinamide that requires methylation for clearance. Additional supportive nutrients may include resveratrol, quercetin, apigenin (CD38 inhibitor), and vitamin B complex.

Side Effects

Commonly Reported Side Effects

NMN has been consistently well tolerated across all published human clinical trials, with minimal adverse events reported. The most commonly reported side effects are mild and transient and include: mild gastrointestinal discomfort (bloating, nausea, or stomach upset), headache, occasional skin flushing (similar to niacin flush, though less common with NMN), insomnia when taken later in the day, and mild fatigue during the initial adjustment period.

Clinical Trial Safety Data

In the first human safety study (Irie et al., 2020), single oral doses of 100 mg, 250 mg, and 500 mg NMN produced no significant changes in heart rate, blood pressure, blood oxygen saturation, body temperature, or sleep quality. No adverse effects were observed.

In the multicenter dose-dependent trial (Yi et al., 2022), daily doses of 300 mg, 600 mg, and 900 mg NMN for 60 days were safe and well tolerated, with no safety issues identified based on adverse event monitoring, laboratory values, or clinical measures.

The high-dose safety study (Yamaguchi et al., 2024) confirmed that 1,250 mg NMN daily for four weeks was safe in healthy adults aged 20 to 65, with no significant adverse events or laboratory abnormalities.

Overall, supplemental doses of NMN ranging from 100 to 1,250 mg per day have demonstrated an excellent safety profile in clinical trials lasting up to 12 weeks. No serious adverse events have been attributed to NMN supplementation in any published human study.

Theoretical Concerns

Some theoretical concerns have been raised in the scientific literature regarding long-term NAD+ precursor supplementation. These include the potential for elevated NAD+ levels to support the growth of pre-existing cancer cells (since cancer cells also rely on NAD+ for metabolism),

possible effects on PARP inhibition when NAD+ levels become excessively high, and the accumulation of nicotinamide metabolites with chronic high-dose use. However, there is currently no clinical evidence in humans that NMN supplementation causes or promotes cancer. On the contrary, some research suggests that NAD+ supplementation may support anti-tumor immunity by boosting the function of immune cells that consume NAD+ when fighting cancer.

Contraindications and Precautions

While NMN has demonstrated an excellent safety profile in clinical trials, certain populations should exercise caution or avoid supplementation until further data are available:

Pregnancy and breastfeeding: No safety data exist for NMN supplementation during pregnancy or lactation. NMN affects cellular metabolism and may influence fetal development. Supplementation should be avoided during these periods unless specifically recommended by a physician.

Active cancer or cancer treatment: Because NAD+ plays a role in the metabolism of both healthy and cancerous cells, individuals with active malignancies or those undergoing chemotherapy or radiation should consult their oncologist before using NMN. The effects of elevated NAD+ on tumor biology are not fully understood.

Liver or kidney disease: The liver and kidneys are involved in the metabolism and clearance of NMN and its metabolites. Individuals with significant hepatic or renal impairment should consult a health-care provider before supplementation.

Medication interactions: NMN may influence insulin sensitivity and blood glucose levels. Individuals taking diabetes medications, blood pressure medications, or other drugs that affect metabolic parameters should consult their physician before starting NMN to avoid potential interactions.

Children and adolescents: NMN supplementation has not been studied in individuals under 18 years of age. NAD+ levels are typically robust in younger populations, and supplementation is generally unnecessary and not recommended for this age group.

Allergies: Individuals with known allergies to any components of NMN supplements (including excipients, fillers, or encapsulation materials) should review product labels carefully and choose third-party-tested products with minimal inactive ingredients.

NMN vs. NR (Nicotinamide Riboside): A Comparison

NMN and nicotinamide riboside (NR) are the two most widely studied NAD+ precursors. Both are effective at raising NAD+ levels, but they differ in molecular structure, metabolic pathway position, and available research. Feature NMN NR Molecular weight 334.22 g/mol 255.25 g/mol Steps to NAD+ One step (NMN → NAD+) Two steps (NR → NMN → NAD+) Key enzyme NMNAT NRK then NMNAT Direct transporter Yes (Slc12a8, discovered 2019) Equilibrative nucleoside transporters FDA status (U.S.) Lawful dietary supplement (2025) GRAS status; dietary supplement Human trials (as of 2024) 12+ completed RCTs 6+ completed RCTs Typical dose range 250–1,250 mg/day 250–1,000 mg/day Stability Sensitive to heat and humidity; cold Also sensitive to degradation; similar storage recommended storage needs Cost Moderate to high Moderate to high (patented forms may cost more)

Both NMN and NR are effective NAD+ precursors with strong safety profiles. NMN’s position one step closer to NAD+ in the biosynthetic pathway and its dedicated transporter (Slc12a8) are often cited as potential advantages, though the clinical significance of these differences is still being investigated. The choice between the two often comes down to personal preference, specific health goals, cost considerations, and product availability.

Success Tips

Start low and build up: Begin with 250 mg per day for the first one to two weeks to assess tolerance, then increase to 500–600 mg daily if well tolerated. This allows the body to adjust to increased NAD+ levels.

Take it in the morning: NMN aligns with the body’s natural circadian NAD+ production cycle. Morning dosing on an empty stomach maximizes absorption and minimizes any risk of sleep disruption.

Consider sublingual delivery: Sublingual NMN powder may bypass first-pass liver metabolism and provide more direct absorption into the bloodstream. Hold the powder under the tongue for 30 to 60 seconds before swallowing.

Support methylation with TMG: NMN metabolism generates nicotinamide, which must be methylated for clearance. Trimethylglycine (TMG) at 500 to 1,000 mg per day supports this methylation burden and helps maintain homocysteine levels.

Add synergistic compounds: Consider co-supplementation with resveratrol (which activates sirtuins), quercetin or apigenin (which inhibit the NAD+-consuming enzyme CD38), and a B- vitamin complex (to support overall NAD+ metabolism). Be consistent: NAD+ levels respond to sustained supplementation. Clinical trials typically required four to twelve weeks to demonstrate measurable benefits. Consistent daily use is more important than taking large intermittent doses.

Choose quality products: Select NMN from reputable manufacturers that provide third-party certificates of analysis confirming purity (≥99%), identity, and absence of contaminants such as heavy metals, solvents, and microbial impurities.

Track your progress: Consider baseline and follow-up testing of blood NAD+ levels (available through some specialty labs) or biological age calculators to objectively monitor the effects of supplementation.

Maintain a healthy lifestyle: NMN supplementation works best as part of a comprehensive approach to healthy aging. Regular exercise, adequate sleep, a nutrient-dense diet, and stress management all contribute to optimizing NAD+ metabolism.

Storage and Handling

Temperature: Store NMN in a cool environment, ideally at refrigerator temperature (2–8°C / 36–46°F). NMN is prone to degradation at temperatures above 28°C (82°F) and can lose significant potency within weeks under warm, humid conditions. If refrigeration is not available, store in a cool, dry location below 25°C (77°F).

Moisture protection: NMN is hygroscopic and absorbs moisture readily, leading to degradation. Keep NMN in an airtight container with a desiccant packet. Ensure the container is sealed immediately after each use. Avoid storing NMN in bathrooms or kitchens where humidity fluctuates.

Light protection: Direct sunlight and UV exposure accelerate NMN degradation. Store in opaque or amber-colored containers, or keep the original packaging in a dark location.

Signs of degradation: Fresh NMN powder should be white to off-white. Yellowing, browning, clumping, unusual odor, or a change in taste may indicate degradation to nicotinamide, which does not provide the same NAD+-boosting benefits and at high doses can inhibit sirtuins and PARPs.

Shelf life: Properly stored NMN powder typically has a shelf life of 12 to 24 months. Stabilized or crystalline forms of NMN may have longer shelf life than non-stabilized forms. Always check expiration dates and follow manufacturer storage guidelines.

Travel: When traveling, keep NMN in its original airtight container, protected from heat and direct sunlight. Consider using a small insulated pouch with a cold pack for trips to warm climates or during summer months.

Handling: Use a clean, dry scoop or measuring spoon to dispense NMN powder. Avoid introducing moisture into the container. If using sublingual powder, ensure hands are dry before handling.

Legal Status

United States

As of September 29, 2025, the U.S. Food and Drug Administration (FDA) has formally confirmed that beta-nicotinamide mononucleotide (NMN) is lawful for use in dietary supplements. This reversed the FDA’s November 2022 determination that NMN was excluded from the dietary supplement definition under the drug preclusion clause of the Federal Food, Drug, and Cosmetic Act. The 2022 exclusion was based on the fact that NMN was under investigation as a new drug (MIB-626 by Metro International Biotech). The Natural Products Association (NPA) and the Alliance for Natural Health USA (ANH) challenged this decision through a citizen petition filed in March 2023 and a federal lawsuit filed in August 2024. The FDA acknowledged that NMN had been marketed as a dietary supplement in the United States as early as 2017, before it was authorized for drug investigation. NMN supplements are now available for purchase through major retailers, including Amazon. NMN remains classified as a New Dietary Ingredient (NDI), and companies must comply with premarket notification requirements under the Dietary Supplement Health and Education Act (DSHEA).

Product Source: For those seeking a high-quality NMN supplement, we recommend sourcing from a reputable manufacturer that offers pure crystalline NMN powder with third-party certificates of analysis confirming greater than 99% purity. Their products are designed for sublingual absorption and are shipped with proper storage protocols to preserve potency. See links below

NMN Pure Powder from Renue by Science

NMN Liposomal Capsules from Renue by Science

Frequently Asked Questions

What is NMN?

NMN (nicotinamide mononucleotide) is a naturally occurring nucleotide that serves as a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production, DNA repair, and hundreds of other metabolic processes.

How does NMN raise NAD+ levels?

NMN is converted directly to NAD+ inside cells by the enzyme NMNAT. Because NMN is only one enzymatic step away from NAD+, it is one of the most efficient precursors for boosting NAD+ levels.

How much NMN should I take daily?

Clinical trials have used doses ranging from 250 mg to 1,250 mg daily. The optimal dose for most adults appears to be 500 to 600 mg per day based on efficacy data from the largest dose- response trial. Beginners may wish to start at 250 mg per day and increase gradually.

When is the best time to take NMN?

Most experts recommend taking NMN in the morning on an empty stomach. This aligns with the body’s natural circadian rhythms for NAD+ production and may help prevent any potential sleep disruption from evening dosing.

Is NMN safe?

NMN has demonstrated an excellent safety profile in all published human clinical trials, with doses up to 1,250 mg daily for four weeks showing no significant adverse events. Most reported side effects are mild and transient, such as occasional stomach discomfort or headache.

Is NMN legal in the United States?

Yes. As of September 29, 2025, the FDA has confirmed that NMN is lawful for use in dietary supplements. The earlier 2022 exclusion was reversed after legal challenges by industry groups. NMN products are now widely available through major retailers.

Does NMN need to be refrigerated?

Refrigeration is recommended, especially for powder forms and in warm or humid climates. NMN can degrade at temperatures above 28°C (82°F), converting to nicotinamide, which does not provide the same NAD+-boosting benefits. Store in an airtight container in a cool, dry, dark location.

What is the difference between NMN and NR?

Both are NAD+ precursors. NMN is one step closer to NAD+ in the biosynthetic pathway and has a dedicated cellular transporter (Slc12a8). NR must first be converted to NMN before becoming NAD+. Both are effective and well tolerated, and the clinical significance of their differences is still being evaluated.

Should I take TMG with NMN?

Many practitioners recommend supplementing with trimethylglycine (TMG) at 500 to 1,000 mg per day when taking NMN. NAD+-consuming enzymes generate nicotinamide, which requires methylation for clearance. TMG helps support this methylation demand and maintain healthy homocysteine levels.

How long does it take to see results from NMN?

Clinical trials have demonstrated measurable increases in blood NAD+ levels within 30 days of supplementation. Subjective benefits such as improved energy, sleep quality, and physical performance have been reported within four to twelve weeks. Consistent daily use is important for optimal results.

Can NMN cause cancer?

There is no clinical evidence that NMN supplementation causes or promotes cancer. However, because NAD+ is utilized by both healthy and cancerous cells, individuals with active malignancies should consult their oncologist before starting NMN supplementation.

Is NMN found in food?

Yes. NMN is present in small amounts in various foods. Broccoli and green beans contain the highest amounts among vegetables studied (up to 13,000 µg per 100 g of fresh weight). Other sources include avocados, edamame, cabbage, cucumbers, and tomatoes. However, dietary intake provides far less NMN than supplemental doses.

Can I combine NMN with other supplements?

Yes. Common synergistic combinations include NMN with resveratrol (sirtuin activator), quercetin or apigenin (CD38 inhibitors), TMG (methylation support), and B vitamins (general

NAD+ pathway support). Always consult a health-care provider when combining multiple supplements, especially with prescription medications.

References

1. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016;24(6):795–806.

2. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513–528.

3. Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism. 2019;1(1):47–57.

4. Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal. 2020;67(2):153–160.

5. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.

6. Huang H. A multicentre, randomised, double blind, parallel design, placebo controlled study to evaluate the efficacy and safety of Uthever (NMN supplement), an orally administered supplementation in middle aged and older adults. Frontiers in Aging. 2022;3:851698.

7. Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29– 43.

8. Kim M, Seol J, Sato T, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults: a randomized, double- blind placebo-controlled study. Nutrients. 2022;14(4):755.

9. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021;18:54.

10. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014;24(8):464–471.

11. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism. 2018;27(3):529–547.

12. Nadeeshani H, Li J, Ying T, et al. Nicotinamide mononucleotide (NMN) as an anti-aging health product – promises and safety concerns. Journal of Advanced Research. 2022;37:267– 278.

13. Song Q, Zhou X, Xu K, et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Advances in Nutrition. 2023;14(6):1416– 1435.

14. Pencina KM, Lavu S, Dos Santos M, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults: a physiologic study. Journal of Clinical Endocrinology and Metabolism. 2023;108(8):1968–1980.

15. Yamaguchi S, Irie J, Mitsuishi M, et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Frontiers in Nutrition. 2024;10:1137637.

16. Liu Y, Gong S, Li K, et al. NMN and NR facilitate NAD+ synthesis via enterohepatic circulation. Science Advances. 2025;11(2):eadr1538.

17. Alegre GFS, Pastore GM. NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR): potential dietary contribution to health. Current Research in Food Science. 2023;6:100502.

18. Zhong O, Wang J, Tan Y, et al. The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications. Frontiers in Pharmacology. 2024;15:1436597.

19. Wen J, Cho I, Park KS, et al. Improved physical performance parameters in patients taking nicotinamide mononucleotide (NMN): a systematic review of randomized control trials. Cureus. 2024;16(8):e66178.

20. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment. Biomolecules. 2020;10(5):687.

21. FDA Citizen Petition Response, September 29, 2025. Confirmation of NMN as lawful dietary supplement ingredient under DSHEA.

22. Di Stefano M, Nascimento-Ferreira I, Orsomando G, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death and Differentiation. 2015;22(5):731–742.

23. Sinclair DA. Keeping NR and NMN supplements cold is crucial. FoundMyFitness. Accessed 2025. 24. Tan Y, Zhong O, Wang J, et al. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta- analysis on randomized controlled trials. Critical Reviews in Food Science and Nutrition. 2024.

25. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Insight into the application of nicotinamide mononucleotide (NMN) to age-related disorders. Biomedical Journal of Scientific and Technical Research. 2024.